Overview

Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as capecitabine, epirubicin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of capecitabine when given together with epirubicin and carboplatin in treating patients with progressive, unresectable, or metastatic cancer.
Phase:
Phase 1
Details
Lead Sponsor:
University of Nebraska
Collaborator:
National Cancer Institute (NCI)
Treatments:
Capecitabine
Carboplatin
Epirubicin